Last reviewed 2026-04-20 · How we verify

Vynfinit (VINTAFOLIDE)

Vynfinit works by binding to folate receptor beta, which is overexpressed in certain cancer cells, and delivering a toxic payload to these cells.

Vynfinit (VINTAFOLIDE) is a small molecule drug in the vintafolide class, originally developed by and currently owned by a pharmaceutical company. It is approved to treat malignant epithelial tumors of the ovary. The commercial status of Vynfinit is not specified, but it is likely patented. Key safety considerations include unknown half-life, bioavailability, and potential side effects. Further research is needed to fully understand its pharmacology and safety profile.

At a glance

Mechanism of action

Imagine a special delivery system that targets cancer cells by binding to a specific receptor on their surface. This receptor is more common in cancer cells than normal cells, so the delivery system can selectively target and kill the cancer cells. This targeted approach helps minimize harm to healthy cells and reduce side effects.

Approved indications

• Malignant epithelial tumor of ovary

Common side effects

No common side effects on file.

Key clinical trials

• Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED) (PHASE3)
• Extension Study of EC145 (Vintafolide) for Subjects Enrolled in a Previous Study With EC145 (MK-8109-010) (PHASE2)
• Phase 2 Study of EC145 Alone Versus EC145+Docetaxel Versus Docetaxel Alone in Participants With FR(++) 2nd Line Non Small Cell Lung Cancer (PHASE2)
• Study of Vintafolide (MK-8109, EC145) in Participants With Progressive Adenocarcinoma of the Lung (MK-8109-008, EC-FV-03) (PHASE2)
• A Study of MK-8109 (Vintafolide) Given Alone or With Chemotherapy in Participants With Advanced Cancers (MK-8109-001) (PHASE1)
• A Study of Vintafolide (MK-8109) in Participants With Advanced Solid Tumor (MK-8109-011) (PHASE1)
• Study of Vintafolide (MK-8109, EC145) in Participants With Advanced Ovarian and Endometrial Cancers (MK-8109-007, EC-FV-02) (PHASE2)
• Platinum Resistant Ovarian Cancer Evaluation of Doxil and Vintafolide (MK-8109, EC145) Combination Therapy (8109-009, EC-FV-04) (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.